Prostate Cancer Experts Preview Trials to Watch at ASCO GU 2026

Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.

Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.

A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.

Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.

After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.